Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2020-05-05 Regulatory Filings
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes of importance to shareholders. The text includes a Regulation FD Disclosure about a press release on clinical data and plans for FDA discussions, and it references an attached press release as Exhibit 99.1. There are no financial statements or detailed financial data presented, only an announcement of a recent event and forward-looking statements. The document is not an Annual Report, Earnings Release, or Interim Report, nor is it a proxy, governance, or management report. It is a regulatory filing used to disclose material events promptly. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is about 5500 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification as a Form 8-K and the nature of the content.
2020-05-05 English
FORM 4
Director's Dealing
2020-05-04 English
FORM 4
Director's Dealing
2020-05-04 English
FORM 4
Director's Dealing
2020-05-04 English
FORM 4
Director's Dealing
2020-05-04 English
FORM 4
Director's Dealing
2020-05-04 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.